ASX-listed breast cancer diagnostic company Volpara Health Technologies has released promising half-year results, with millions in revenue growth despite massive disruption to cancer diagnostics with Covid-19.
However, growing losses appeared to spook investors, and the company’s share
Want to read more? It's easy.
Choose your best value subscription option
Student
Exclusive offer for uni students studying at a New Zealand university (valued at $499).
